AI’s double-edged future: bioweapon fears, security blind spots, and a widening US–China trust gap

AI is moving from lab to operations faster than governance can keep up, and multiple reports converge on the same strategic anxiety: the technology could be used to accelerate biological harm. Arthur Holland Michel warns that “at some point in the very, very near future” AI may help create new or more deadly bioweapons, framing the threat as a near-term capability shift rather than a distant hypothetical. Separately, analysis of “agentic AI” argues that systems already execute tasks, consume data, and take actions in production environments with limited meaningful involvement from security teams. Together, these narratives suggest a security posture problem—AI is becoming an operational actor, not just a tool—while oversight remains largely policy-discussion rather than control-by-design. Geopolitically, the AI security debate is landing on top of a broader erosion of trust between Washington and Beijing. Commentary that China increasingly views “Trump’s America as an empire in decline” signals that strategic narratives are hardening, even as the US domestic conversation about AI remains split between Silicon Valley optimism and public dread. This combination matters because it shapes how states interpret intent, manage escalation, and decide whether to cooperate on risk reduction or compete on capability. The result is a risk of miscalculation: if both sides assume the other is racing ahead, transparency and verification become politically costly, and “security blind spots” can become strategic vulnerabilities. Markets are also absorbing the shockwaves, though through different channels than bioweapon fears. German firms operating in China reportedly grew more optimistic about the economic outlook despite the Iran war and persistent trade tensions, according to a survey by the German Chamber of Commerce in China—an indicator that some supply-chain and demand expectations are stabilizing. At the same time, domestic German industrial leadership is sounding alarm bells about how severe the situation is, with commentary from Trumpf’s Nicola Leibinger-Kammüller implying that the economic pain is deeper than the public remembers from earlier crises. For investors, the immediate linkage is less about AI itself and more about how security and geopolitical uncertainty feed into risk premia for industrial exporters, semicap/automation supply chains, and trade-sensitive manufacturing. What to watch next is whether AI governance evolves into enforceable security controls and whether states translate rhetoric into concrete biosecurity and cyber/critical-infrastructure safeguards. Key indicators include: new guidance on agentic AI deployment, incident reporting requirements for autonomous or semi-autonomous systems, and any movement toward verification mechanisms for high-risk biotech workflows. On the geopolitical side, watch for further US–China narrative hardening tied to the political framing of “decline” and for any policy signals from Washington that change how AI risk is treated in national security planning. In parallel, monitor German business sentiment and industrial output signals for evidence that trade tensions and the Iran war are either being absorbed or re-escalating into cost shocks for exporters.

Geopolitical Implications

• 01

  Biosecurity and AI governance are becoming intertwined national-security issues, potentially accelerating regulation and export controls on dual-use capabilities.

• 02

  Agentic AI expands the surface area for cyber and critical-infrastructure risk, increasing the likelihood of state and corporate security mandates.

• 03

  Strategic mistrust between Washington and Beijing can reduce transparency and verification, making escalation management harder during crises.

• 04

  Trade and security uncertainty continue to shape industrial investment decisions in Germany’s China-linked manufacturing ecosystem.

Key Signals

• —Any concrete US/EU guidance that operationalizes agentic AI security controls (logging, permissioning, human-in-the-loop thresholds).
• —Biosecurity policy proposals tied to AI-assisted biotech workflows, including auditability and oversight requirements.
• —New US–China statements that further entrench “decline” narratives or propose verification/coordination mechanisms.
• —Next German Chamber of Commerce in China survey waves and German industrial output/PMI indicators for exporter stress.